<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34862669</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1346-8138</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>49</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of dermatology</Title>
          <ISOAbbreviation>J Dermatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Flare-up of generalized pustular psoriasis combined with systemic capillary leak syndrome after coronavirus disease 2019 mRNA vaccination.</ArticleTitle>
        <Pagination>
          <StartPage>454</StartPage>
          <EndPage>458</EndPage>
          <MedlinePgn>454-458</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/1346-8138.16271</ELocationID>
        <Abstract>
          <AbstractText>Generalized pustular psoriasis (GPP) is characterized by acute flare-ups induced by various factors, but few reports have described GPP onset or flare-up induced by vaccination. To our knowledge, only three such cases following coronavirus disease 2019 (COVID-19) vaccination have been reported. We herein report a case of GPP flare-up after COVID-19 mRNA vaccination. A 65-year-old man with GPP controlled by infliximab presented with widespread pustular erythema, fever, and malaise following his second COVID-19 mRNA vaccination. A skin eruption was apparent at the injection site. He also exhibited systemic capillary leak syndrome (SCLS), which responded rapidly to secukinumab and systemic corticosteroids. Two biopsies, one of which was of the injection site, revealed not only findings typical of GPP, but also a dermal mixed-cell infiltration with eosinophils, and microthrombi in the small dermal vessels. The latter findings have been observed in cutaneous lesions induced by both COVID-19 infection and vaccination. This is the first case of a GPP flare-up accompanied by SCLS induced by a COVID-19 mRNA vaccine. Also, this is the first flare-up induced by the second vaccine dose, and the first such report including detailed histological data, including for the injection site.</AbstractText>
          <CopyrightInformation>© 2021 Japanese Dermatological Association.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yatsuzuka</LastName>
            <ForeName>Kazuki</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0001-7747-0551</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Ehime University Graduate School of Medicine, Toon, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Murakami</LastName>
            <ForeName>Masamoto</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-3923-5096</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Ehime University Graduate School of Medicine, Toon, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuroo</LastName>
            <ForeName>Yuta</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Ehime University Graduate School of Medicine, Toon, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fukui</LastName>
            <ForeName>Maiko</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Ehime University Graduate School of Medicine, Toon, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoshida</LastName>
            <ForeName>Satoshi</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-3945-4459</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Ehime University Graduate School of Medicine, Toon, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Muto</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Ehime University Graduate School of Medicine, Toon, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shiraishi</LastName>
            <ForeName>Ken</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-1153-7749</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Ehime University Graduate School of Medicine, Toon, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sayama</LastName>
            <ForeName>Koji</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Ehime University Graduate School of Medicine, Toon, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Dermatol</MedlineTA>
        <NlmUniqueID>7600545</NlmUniqueID>
        <ISSNLinking>0385-2407</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000711953">mRNA Vaccine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019559" MajorTopicYN="Y">Capillary Leak Syndrome</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011565" MajorTopicYN="Y">Psoriasis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">coronavirus disease 2019</Keyword>
        <Keyword MajorTopicYN="N">flare-up</Keyword>
        <Keyword MajorTopicYN="N">pustular psoriasis</Keyword>
        <Keyword MajorTopicYN="N">systemic capillary leak syndrome</Keyword>
        <Keyword MajorTopicYN="N">vaccines</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34862669</ArticleId>
        <ArticleId IdType="doi">10.1111/1346-8138.16271</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Sbidian E, Eftekahri P, Viguier M, Laroche L, Chosidow O, Gosselin P, et al. National survey of psoriasis flares after 2009 monovalent H1N1/seasonal vaccines. Dermatology. 2014;229:130-5.</Citation>
        </Reference>
        <Reference>
          <Citation>Onsun N, Kaya G, Isik BG, Gunes B. A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report. Health Promot Perspect. 2021;11:261-2.</Citation>
        </Reference>
        <Reference>
          <Citation>Elamin S, Hinds F, Tolland J. A case of de novo generalised pustular psoriasis following Oxford-AstraZeneca COVID-19 Vaccine. Clin Exp Dermatol. 2021. https://doi.org/10.1111/ced.14895</Citation>
        </Reference>
        <Reference>
          <Citation>Perna D, Jones J, Schadt CR. Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine. JAAD Case Rep. 2021;17:1-3.</Citation>
        </Reference>
        <Reference>
          <Citation>Syversen SW, Goll GL, Jorgensen KK, Olsen IC, Sandanger Ø, Gehin JE, et al. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study). Trials. 2020;21:13.</Citation>
        </Reference>
        <Reference>
          <Citation>Samotij D, Szczech J, Reich A. Generalized pustular psoriasis: divergence of innate and adaptive immunity. Int J Mol Sci. 2021;22:9048.</Citation>
        </Reference>
        <Reference>
          <Citation>Gianotti R, Zerbi P, Dodiuk-Gad RP. Clinical and histopathological study of skin dermatoses in patients affected by COVID-19 infection in the Northern part of Italy. J Dermatol Sci. 2020;98:141-3.</Citation>
        </Reference>
        <Reference>
          <Citation>Larson V, Seidenberg R, Caplan A, Brinster NK, Meehan SA, Kim RH. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol. 2021. https://doi.org/10.1111/cup.14104</Citation>
        </Reference>
        <Reference>
          <Citation>Ohsawa R, Sano H, Ikeda M, Sano S. Clinical and histopathological views of morbilliform rash after COVID-19 mRNA vaccination mimic those in SARS-CoV-2 virus infection-associated cutaneous manifestations. J Dermatol Sci. 2021;103:124-7.</Citation>
        </Reference>
        <Reference>
          <Citation>Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy. Int J Mol Sci. 2016;17:1214.</Citation>
        </Reference>
        <Reference>
          <Citation>Agaronov A, Makdesi C, Hall CS. Acute generalized exanthematous pustulosis induced by Moderna COVID-19 messenger RNA vaccine. JAAD Case Rep. 2021;16:96-7.</Citation>
        </Reference>
        <Reference>
          <Citation>Druey KM, Parikh SM. Idiopathic systemic capillary leak syndrome (Clarkson disease). J Allergy Clin Immunol. 2017;140:663-70.</Citation>
        </Reference>
        <Reference>
          <Citation>Bressan AL, Pereira D, Medeiros PM, Carneiro S, Azulay-Abulafia L. How relevant are vascular endothelial growth factor and intercellular adhesion molecule in the systemic capillary leak syndrome of psoriasis? An Bras Dermatol. 2017;92:826-9.</Citation>
        </Reference>
        <Reference>
          <Citation>Druey KM, Greipp PR. Narrative review: the systemic capillary leak syndrome. Ann Intern Med. 2010;153:90-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Vos LE, Vermeer MH, Pavel S. Acitretin induces capillary leak syndrome in a patient with pustular psoriasis. J Am Acad Dermatol. 2007;56:339-42.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
